Trials / Not Yet Recruiting
Not Yet RecruitingNCT07451054
CD45BE-HSPC + CART-45 Cells
Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
Conditions
- B-Cell Non-Hodgkin Lymphoma (NHL)
- Richter's Transformation
- T-Cell Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CART-45 cells | Autologous base edited anti-CD45 CAR T cells |
| BIOLOGICAL | CD45BE-HSPC | CD45 base edited hematopoietic stem and progenitor cells |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2043-04-01
- Completion
- 2043-04-01
- First posted
- 2026-03-05
- Last updated
- 2026-03-05
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07451054. Inclusion in this directory is not an endorsement.